SCHEMBL16616158

SCHEMBL16616158

COc1ccc(Nc2ncccc2/C=C/C(=O)c2cccnc2Nc2ccccc2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.51
MAPK9 P45984 1/20 0.51
MEN1 O00255 8/20 0.50
KMT2A Q03164 8/20 0.50
MAPT P10636 6/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPK1 P28482 2/20 0.50
RAB9A P51151 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
HTT P42858 2/20 0.49
PKM P14618 1/20 0.49
NPC1 O15118 1/20 0.49
DHODH Q02127 1/20 0.47
ABCG2 Q9UNQ0 7/20 0.47
ABCB1 P08183 4/20 0.47
GAA P10253 2/20 0.45
POLB P06746 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16616159 1.00 MAPK8 (0.51) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616544 0.93 NPSR1 (0.56) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616614 0.93 RAB9A (0.46) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616542 0.93 NPSR1 (0.56) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616612 0.93 RAB9A (0.46) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616822 0.92 DHODH (0.50) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616823 0.92 DHODH (0.50) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616594 0.91 MAPK9 (0.47) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616591 0.91 MAPK9 (0.47) MAPK8MAPK9MEN1KMT2AMAPT
SCHEMBL16616561 0.90 TEK (0.49) MAPK9MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof HCCS, WEE2, WEE1 MAPK8 1397/4885MAPK9 207/4885MEN1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.